We are nearing a point of no return for GLP-1 drugs. More than one in 10 Americans have already taken a GLP-1 agonist, be it ...

Ozempic and its counterparts, including Wegovy, Mounjaro and Zepbound, have surged in popularity as a means for weight loss, fueled by celebrity endorsements and slick pharmaceutical marketing.